13. 12. 2024
The establishment of the National Institute for Cancer Research (NICR) was truly a turning point in the Czech Republic's commitment to advancing cancer research, prevention, and treatment. As the Chair of the International Supervisory and Advisory Board (ISAB), I have the privilege of closely witnessing NICR’s evolution into a hub of scientific excellence, innovation, and collaboration. From an external perspective, the progress it achieved in just two years is remarkable.
16. 10. 2024
Recently, I have encountered on the X network a post by Marek Ženíšek, the Minister for Science, Research, and Innovations, where he with pleasure announced an increase in the budget for science, research, and innovations for 2025. Although one could debate whether the increase is sufficient, it left me with a good feeling – just until I glanced at the chain of reactions. The list was rather long and without exception full of negative reactions! Reactions to the minister as such, to budget priorities, but especially to science and scientists. How is it possible?
22. 8. 2024
To discuss with colleagues the importance of internationalisation for scientific work – be it at the level of money, information, personnel, experts, or the formation of consortia – would be like the proverbial taking of owls to Athens. But unfortunately, I know from my own experience that not all administrative staff of the co-recipients quite understand the importance of internationalisation, starting from the content of scientific work all the way to its impact on reputation.
12. 6. 2024
But there is! And NICR is responsible for some of it. It is because the mission of the National Institute for Cancer Research includes not only top-quality research but also other specialised and educational activities, to use the vocabulary of project calls.
12. 4. 2024
It is our pleasure to inform you about the creation of two unique doctoral programmes created in collaboration with the National Institute for Cancer Research (NICR) and under its patronage. The two programmes are Molecular and Translational Medicine at the Palacký University, Olomouc, and Experimental and Clinical Oncology at the Charles University.